Aloxi Articles
Helsinn moving forward with supportive cancer care products anamorelin and netupitant + palonosetron
26 September 2011
Helsinn licenses anti-nausea drug Aloxi to Specialised Therapeutics for Australian and New Zealand cancer patients
2 November 2010
Batch of Japanese drug approvals, including for Taiho, Daiichi Sankyo and three for Novartis
20 January 2010
Variquel key to IS Pharma’s growth, says Edison
19 January 2010
Eisai profit down 38% on MGI acquisition
16 February 2009
Helsinn Birex plant in Ireland gets authorization
15 December 2008
Eisai profit down 27% on MGI acquisition
24 November 2008
AP Pharma's APF530 ready for submission
6 October 2008
Japan stock market week to Sept 1, 2008
8 September 2008
Eisai/Helsinn's Aloxi capsules approved in USA
1 September 2008
Japan stock market week to July 14, 2008
21 July 2008
Aloxi launched in USA for PONV
14 July 2008
Eisai's fiscal 2007 hit by MGI Pharma buy
2 June 2008
Japan stock market week to March 10, 2008
17 March 2008
Eisai/MGI's Aloxi gets expanded indication
10 March 2008
Biovitrum's earnings flat on expenses
3 March 2008
Helsinn licenses Aloxi and Gelclair to Riemser Arzneimittel
18 February 2008
Helsinn Healthcare's Aloxi launched in UK
18 February 2008
MGI Pharma leaps on hiring advisors
10 December 2007
Biovitrum's 2nd-qtr 2007 income soars 33%
10 September 2007
FDA accepts Helsinn's Aloxi sNDA
16 July 2007
MGI and Helsinn submit Aloxi sNDA
14 May 2007
MGI's 1st-qtr 2007 net income rises to $83.2M
30 April 2007
Biovitrum's FY 2006 net profit plummets 47.4%
5 March 2007
MGI's 4th-qtr 2006 net loss narrows to $19.6M
19 February 2007
MGI/Helsinn's Aloxi meets Ph III endpoints
22 December 2006
MGI Pharma moves into loss for 2nd-qtr
24 July 2006
Helsinn and Biovitrum agree Aloxi distribution deal
20 February 2006
19 additions to Italy's reimbursement list
20 February 2006
UPDATE: MGI Pharma makes $178M bid for Guilford, plus assuming $69.4M convertible debt
1 August 2005
Helsinn and Angelini enter deal
11 July 2005
MGI reports 241% 1st qtr revenue jump
25 April 2005
Helsinn licenses Aloxi to ribosepharm
14 February 2005
Helsinn and Kable in Aloxi marketing deal
17 January 2005
CHMP issues positive opinion on palonosetron
10 January 2005
MGI's 3rd-qtr losses rocket on acquisitions
25 October 2004
MGI Pharma's 2nd-qtr sales rocket to $46.9M
26 July 2004
MGI Pharma sees 1st-qtr sales surge 298%
19 April 2004
Helsinn and Taiho sign deal for palonosetron
9 February 2004
New Chemical Entities in 2003
19 January 2004
MGI Pharma/Helsinn's Aloxi gets US approval
4 August 2003
Showing 1-45 of 45 articles
- 1
- Is failure to adopt business process management putting the pharma industry at risk?
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Elan makes "transformational" acquisitions and a divestment
